SCHEMBL700968

SCHEMBL700968

CCCC(=O)Oc1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
LMNA P02545 1/20 0.42
TSHR P16473 2/20 0.41
BCL9 O00512 1/20 0.41
CTNNB1 P35222 1/20 0.41
RAB9A P51151 3/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
PTGS2 P35354 1/20 0.40
ALDH1A1 P00352 4/20 0.40
CYP1A2 P05177 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
RECQL P46063 1/20 0.40
ALOX15 P16050 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20267237 0.90 KDM4E (0.51) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL30906981 0.90 KDM4E (0.51) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL7027502 0.87 LMNA (0.48) LMNARAB9AKMT2ASMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL7858307 0.86 LMNA (0.47) LMNARAB9AKMT2ASMN1; SMN2NPC1
SCHEMBL30571184 0.86 ALDH1A1 (0.45) LMNATSHRRAB9AKMT2ASMN1; SMN2
SCHEMBL14501436 0.86 SMN1; SMN2 (0.44) LMNATSHRCTNNB1RAB9AKMT2A
SCHEMBL4996914 0.86 ALDH1A1 (0.45) LMNATSHRRAB9AKMT2ASMN1; SMN2
Bromide SCHEMBL28268585 0.84 ALDH1A1 (0.44) LMNATSHRRAB9AKMT2ASMN1; SMN2
SCHEMBL9202850 0.83 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL6246507 0.83 TSHR (0.38) PDE4APDE4BPDE4CPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735586-B2 Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI (FR) 2014-05-27 US claimed
EP-2173721-B1 A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI SA (FR) 2011-12-28 EP claimed
EP-2173747-B1 A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI SA (FR) 2011-12-21 EP claimed
US-20100261909-A1 Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2010-10-14 US claimed
US-20100216988-A1 Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2010-08-26 US claimed
EP-2173721-A1 A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES Sanofi-Aventis (FR) 2010-04-14 EP claimed
EP-2173747-A1 A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES Sanofi-Aventis (FR) 2010-04-14 EP claimed
CN-101687815-A Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles SANOFI AVENTIS 2010-03-31 CN claimed
CN-101687865-A A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles SANOFI AVENTIS 2010-03-31 CN claimed
WO-2009000413-A1 A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI-AVENTIS (FR) 2008-12-31 WO claimed
WO-2009000412-A1 A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI AVENTIS (FR) 2008-12-31 WO claimed
US-4948894-A BACTERICIDE INTERMEDIATES AMERICAN CYANAMID COMPANY (US) 1990-08-14 US claimed
EP-3614113-B1 TEMPERATURE DETECTING MATERIAL AND PRODUCT CONTROL METHOD HITACHI INDUSTRY EQUIPMENT SYSTEMS CO LTD (JP) 2024-07-17 EP disclosed
US-11933677-B2 Temperature detecting material, temperature detecting ink using same, temperature indicator, and product control system HITACHI INDUSTRIAL EQUIPMENT SYSTEMS CO., LTD. (JP) 2024-03-19 US disclosed
WO-2024043319-A1 ANTIBODY-DRUG COMPLEX エーザイ・アール・アンド・ディー・マネジメント株式会社 2024-02-29 WO disclosed
EP-4281452-A1 MODULATORS OF FPR1 AND METHODS OF USING THE SAME Beijing Tiantan Hospital (CN) 2023-11-29 EP disclosed
US-4698349-A Quinolizinone compounds, and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-10-06 US disclosed
US-4650804-A TETRAZOLYLCARBAMOYL DERIVATIVE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-03-17 US disclosed
EP-0157346-A2 Quinolizinone compound, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-10-09 EP disclosed
US-3993656-A BRONCHODILATOR, HYPOTENSIVES MERCK & CO., INC. (US) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261909-A1 Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles AZI2, NISCH, UQCRB PDE4A 1869/4885PDE4B 1802/4885PDE4C 2706/4885
US-20100216988-A1 Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles AZI2, NIT2, NISCH PDE4A 2010/4885PDE4B 1780/4885PDE4C 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.